Shin Nippon Biomedical Laboratories, Ltd.
2395.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.10 | -1.30 | -1.26 | 0.10 |
| FCF Yield | -6.41% | -10.39% | -0.83% | 6.14% |
| EV / EBITDA | 9.29 | 8.74 | 12.94 | 7.71 |
| Quality | ||||
| ROIC | 3.22% | 5.44% | 9.06% | 12.72% |
| Gross Margin | 51.12% | 54.00% | 52.00% | 54.58% |
| Cash Conversion Ratio | 1.43 | 0.38 | 0.52 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.91% | 14.22% | 18.42% | 6.82% |
| Free Cash Flow Growth | 41.24% | -582.84% | -121.94% | 19.56% |
| Safety | ||||
| Net Debt / EBITDA | 2.54 | 1.77 | 0.87 | 0.26 |
| Interest Coverage | 14.72 | 29.99 | 41.94 | 33.13 |
| Efficiency | ||||
| Inventory Turnover | 1.26 | 0.98 | 1.64 | 1.85 |
| Cash Conversion Cycle | 353.42 | 436.31 | 277.69 | 266.43 |